What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dose Escalation Part: In this part, 6 dose levels are planned and approximately 30 patients will be enrolled. After each dose level, Safety Review Committee (SRC) will evaluate the available safety, tolerability, PK of YH32364 to decide the next dose. Dose Expansion Part: 50 participants with previously treated locally advanced or metastatic EGFR overexpressing HNSCC other than NPC will be…”In the company’s words, NCT06975410 on ClinicalTrials.gov
- Tested for
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Main trialPhase 1/2
- “This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.”In the company’s words, NCT06975410 on ClinicalTrials.gov
Other drugs for Locally Advanced Solid Tumor
- FutibatinibTaiho · Phase 2/3
- TinengotinibTransThera Sciences (Nanjing), Inc. · Phase 3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
Coming up1
- Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jun 2027 | Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026